Faculty Opinions recommendation of Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery.

Author(s):  
Charles Coutelle
2008 ◽  
Vol 40 (2) ◽  
pp. 278 ◽  
Author(s):  
A. Lombardo ◽  
P. Genovese ◽  
C.M. Beausejour ◽  
S. Colleoni ◽  
Y.-L. Lee ◽  
...  

2007 ◽  
Vol 25 (11) ◽  
pp. 1298-1306 ◽  
Author(s):  
Angelo Lombardo ◽  
Pietro Genovese ◽  
Christian M Beausejour ◽  
Silvia Colleoni ◽  
Ya-Li Lee ◽  
...  

2011 ◽  
Vol 19 (5) ◽  
pp. 942-950 ◽  
Author(s):  
Yuning Lei ◽  
Chi-Lin Lee ◽  
Kye-Il Joo ◽  
Jonathan Zarzar ◽  
Yarong Liu ◽  
...  

2014 ◽  
Vol 14 (5) ◽  
pp. 365-376 ◽  
Author(s):  
Abarrategui-Pontes Cecilia ◽  
Creneguy Alison ◽  
Thinard Reynald ◽  
Fine J. ◽  
Thepenier Virginie ◽  
...  

PLoS ONE ◽  
2011 ◽  
Vol 6 (12) ◽  
pp. e28911 ◽  
Author(s):  
Anna Osiak ◽  
Frank Radecke ◽  
Eva Guhl ◽  
Sarah Radecke ◽  
Nadine Dannemann ◽  
...  

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. SCI-12-SCI-12
Author(s):  
Fyodor D. Urnov

Abstract The ability to engineer precise genetic modification of human stem cells offers the promise to extend the range of their potential therapeutic application. This possibility is now being realized via the use of zinc finger nucleases (ZFNs). ZFNs are customizable, sequence-specific endonucleases that can be designed to introduce a discrete cleavage event at any user-chosen location within the stem cell genome. This presentation will describe our progress in translating ZFN-modified hematopoietic stem/progenitor cells (HSPCs) from concept to clinic, focusing on preclinical proof-of-concept studies supporting the development of autologous, genome-edited CD34+ HSPCs as potential treatments for both HIV/AIDS as well as certain monogenic diseases of the blood, such as β-thalassemia. Disclosures Urnov: Sangamo BioSciences: Employment.


Sign in / Sign up

Export Citation Format

Share Document